Alternative stem cell therapy in patients with ulcerative colitis

Authors

Keywords:

STEM CELLS, COLITIS, ULCERATIVE, IMMUNOTHERAPY, ADOPTIVE.

Abstract

Introduction: ulcerative colitis is a chronic, inflammatory, ulcerative and relapsing disease of the gastrointestinal tract, which evolves by relapses.

Objective: to determine the effectiveness of alternative treatment with stem cells in patients diagnosed with ulcerative colitis at Abel Santamaria Cuadrado General Teaching Hospital, Pinar del Rio province in the period of 2018-2020.

Methods: a descriptive, longitudinal and prospective study was conducted. The target group consisted of 425 patients and the sample comprised 135 patients with a diagnosis of ulcerative colitis who met the inclusion criteria. Individual medical records were reviewed.

Results: the age group 45-54 years (44 %) and female sex (59,25 %) predominated. Poor dietary habits (65,1 %), medication intake (40 %) and smoking (32,5 %) predominated, as well as a family history of ulcerative colitis (48.1 %). Mucous bloody stools (65,1 %), rectorrhagia (48,1 %) and abdominal pain (23,7 %)  predominated,  as  well  as the endoscopic method (69,6 %). A satisfactory evolution (93,5 %) was observed with the application of stem cell therapy.

Conclusions: female sex and the age group 45-54 years were predominant. The main risk factors were poor dietary habits and medication intake. Ulcerative colitis predominated as a family pathological history. Mucous bloody stools, rectorrhagia and abdominal pain were the most relevant symptoms. The endoscopic procedure was the most important method and the effectiveness of the alternative method with autologous stem cells was demonstrated.

Downloads

Download data is not yet available.

Author Biographies

Yantiel Frances-Acosta, Hospital General Docente Abel Santamaria Cuadrado

Especialista de primer grado de MGI y Gastroenterología

Medardo Rodriguez-Lopez, Hospital General Docente Abel Santamaria Cuadrado

Hospital general Docente Abel Santamaria Cuadrado

Adisnubia Martín Ruiz, Hospital General Docente Abel Santamaria Cuadrado

Especialista de primer grado de MGI y Gastroenterología

Abel Pimienta Lorenzo, Hospital General Docente Abel Santamaria Cuadrado

Especialista de primer grado de MGI y Gastroenterología

References

1. Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: Current and future directions. Clin Gastroenterol Hepatol [Internet]. 2016[Citado: 25/01/2021]; 14(3): 348-54. Disponible en: https://doi.org/10.1016/j.cgh.2015.06.001

2. R.K. Burt, Y. Loh, W. Pearce, N. Beohar, W.G. Barr, R. Craig, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA [Internet]. 2008 [Citado: 25/01/2021]; 299(8): 925-936. Disponible en: http://dx.doi.org/10.1001/jama.299.8.925

3. Gonzalez-Pujana A, Vining KH, Zhang DKY, Santos-Vizcaino E, Igartua M, Hernandez RM, et al. Multifunctional biomimetic hydrogel systems to boost the immunomodulatory potential of mesenchymal stromal cells. Biomaterials [Internet]. 2020 [Citado: 25/01/2021]; 257: 120266. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32763614/

4. Taxonera C. Specialist care in the management of inflammatory bowel disease. Rev. esp. enferm. Dig. [Internet]. 2016 [Citado: 25/01/2021]; 108(10): 607-608. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082016001000001&lng=es.

5. López Cortés R, Marín Fernández B, Hueso Montoro C, Escalada Hernández P, Sanz Aznarez AC, Rodríguez Gutiérrez C. Calidad de vida relacionada con la salud en pacientes con enfermedad inflamatoria intestinal. Anales Sis San Navarra [Internet]. 2016 [Citado: 25/01/2021]; 39(1): 123-131. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137-66272016000100014&lng=es.

6. Paredes-Méndez J, Otoya-Moreno G, Mestanza-Rivas-Plata AL, Lazo-Molina L, Acuña-Ordoñez K, Arenas-Gamio JL et al. Características epidemiológicas y clínicas de la enfermedad inflamatoria intestinal en un hospital de referencia de Lima-Perú. Rev. gastroenterol. Perú [Internet]. 2016 [Citado: 25/01/2021]; 36(3): 209-218. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1022-51292016000300004&lng=es

7. Hano García OM, Andrade Gomes S, Villa Jiménez OM, González Fabian L, Wood Rodríguez L. Caracterización de pacientes con colitis ulcerosa atendidos en centro de nivel terciario. Rev cubana med [Internet]. 2016 Mar [citado 20/12/2021]; 55(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232016000100005&lng=es

8. Bufadel ME. Enfermedades inflamatorias intestinales [Tesis]. Universidad de Chile; 2019. [Citado: 25/01/2021]. Disponible en: file:///C:/Users/MEDICOS/Desktop/HACER/Tesis%20CU%20Leidy/Bibliografía%20tesis%20CU/1

9. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut [Internet]. 2011 [Citado: 25/01/2021]; 60(6): 780-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21209123/

10. Meligrana NE, Quera R, Figueroa C, Ibáñez P, Lubascher J, Kronberg U, et al. Factores ambientales en el desarrollo y evolución de la enfermedad inflamatoria intestinal. Rev. méd. Chile [Internet]. 2019 [Citado: 25/01/2021]; 147(2): 212-220. Disponible en: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000200212&lng=es.

11. Spekhorst LM, Visschedijk MC, Alberts R, Festen EA, et al. Performance of the Montreal classification for inflammatory bowel diseases. World J Gastroenterol. [Internet]. 2014 [Citado: 25/01/2021]; 20(41): 15374–15381. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223272/

12. García O. Enfermedad inflamatoria intestinal y células madres. [Internet]. 2018 [Citado: 25/01/2021]; 10(7): Disponible: https://isanidad.com/158570/dr-garcia-olmo-propiedades-antiinflamatorias-celulas-madres

13. Medina B E. Enfermedad inflamatoria intestinal. Protocolos diagnóstico-terapéuticos de Gastroenterología, Hepatología y Nutrición Pediátrica SEGHNP-AEP [Internet]. Madrid; 2019 [Citado: 25/01/2021]. P151-160. Disponible en: https://www.aeped.es/sites/default/files/documentos/eii.pdf

14. Yamamoto-Furusho JK, Bosques-Padilla F, de-Paula J, Galiano MT, Ibañez P, Juliao F, et al. Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. Rev Gastroenterol Mex [Internet]. 2017 [Citado 25/01/2021]; 82(1): 46-84. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27979414/

15. Sánchez A, Caballo-Escribano C. Funcionamiento y calidad de vida en personas con enfermedades crónicas: poder predictivo de distintas variables psicológicas. Enferm. glob [Internet]. 2017 [Citado: 25/01/2021]; 16(46): 281-294. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1695-

16. Fernández Martín C, Martín Maroto C, Salazar Fernández L. Evaluación mediante las redes sociales de la información con la que cuentan los pacientes con EII. Rev. esp. enferm. dig. [Internet]. 2018 [Citado: 25/01/2021]; 110(5): 274-284. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082018000500002

17. Jauregui-Amezaga A, Geerits A, Das Y, Lemmens B, Sagaert X, Bessissow T, et al. A Simplified Geboes Score for Ulcerative Colitis. J Crohns Colitis [Internet]. 2017 [Citado: 25/01/2021]; 11(3):305-313. Disponible en : https://pubmed.ncbi.nlm.nih.gov/27571771/

Downloads

Published

2021-12-21

How to Cite

1.
Frances-Acosta Y, Rodriguez-Lopez M, Martín Ruiz A, Pimienta Lorenzo A, Mayor Porras A. Alternative stem cell therapy in patients with ulcerative colitis. Rev Ciencias Médicas [Internet]. 2021 Dec. 21 [cited 2025 Dec. 25];25(6):e5347. Available from: https://revcmpinar.sld.cu/index.php/publicaciones/article/view/5347

Issue

Vol. 25 No. 6 (2021)

Section

ORIGINAL ARTICLES

License

Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.

Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/